Acute Lymphoblastic Leukemia

Protocol ID

Official Title

Principal Investigator

Lead CRC

Disease Site

Phase

Ponatinib-3001

ClinicalTrials.gov #

NCT03589326

A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib versus Imatinib, Administered in Combination with Reduced-intensity Chemotherapy, in Patients with Newly Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL) Protocol Dr. Vamsi Kota   Acute Lymphoblastic Leukemia III

Acute Myeloid Leukemia

Protocol ID

Official Title

Principal Investigator

Lead CRC

Disease Site

Phase

PrE0905

ClinicalTrials.gov #

NCT03836209

Randomized Trial of Gilteritinib vs. Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML) Dr. Vamsi Kota   Acute Myeloid Leukemia  

D18-11141

ClinicalTrials.gov: #

NCT03926624

Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine) or Intensive
Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second or
Third Salvage
Dr. Jorge Cortes   Acute Myelogenous Leukemia III

SLSG18-301

ClinicalTrials.gov: #

NCT04229979

Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S Maintenance Therapy Compared to Best
Available Therapy in Acute Myeloid Leukemia Patients Who Have Achieved Complete Remission After Second-Line
Salvage Therapy
Dr. Jorge Cortes   Acute Myelogenous Leukemia  

PRT543-01

ClinicalTrials.gov: #

NCT03886831

A Phase I, Open-Label, Multicenter, Dose Escalation, Dose Expansion Study of PRT543 in Patients with Advanced Solid
Tumors and Hematologic Malignancies
Dr. Jorge Cortes  

Large B-cell Lymphoma

Myelodysplasia,

Myelofibrosis

Mantle Cell Lymphoma

Acute Myeloid Leukemia

Myelomonocytic Leukemia

I

Chronic Lymphocytic Leukemia

Protocol ID

Official Name

Principal Investigator

Lead CRC

Disease Site

Phase

A041702

Clinicaltrials.gov #

NCT03737981

A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 Years of Age) with Chronic Lymphocytic Leukemia Dr. Locke Bryan   Chronic Lymphocytic Leukemia III

Chronic Myeloid Leukemia

Protocol ID

Official Name

Principal Investigator

Lead CRC

Disease Site

Phase

CLR-15-03

ClinicalTrials.gov: #

NCT02629692

A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Dr. Jorge Cortes  

Chronic Myeloid Leukemia

Acute Lymphoblastc Leukemia

I/II

KRT-232-117

ClinicalTrials.gov #

NCT04835584

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with a Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed or Refractory Ph+ Chronic Myeloid Leukemia (CML) Dr. Jorge Cortes   Chronic Myeloid Leukemia Ib/II

Lymphoma

Protocl ID

Official Name

Principal Investigator

Lead CRC

Disease Site

Phase

BP1002-101-Lymph

ClinicalTrials.gov: #

NCT04072458

A Phase I Clinical Trial to Study the Safety, Pharmacokinetics, and Efficacy of BP1002 (L-Bcl-2) Antisense Oligonucleotide in Patients with Advanced Lymphoid Malignancies Dr. Locke Bryan   Lymphomas and Leuekemias I

A051301

ClinicalTrials.gov #

NCT02443077

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of the Activated B-cell Subtype Dr. Locke Bryan   Large B-Cell Lymphoma III

EA4151

ClinicalTrials.gov: #

NCT03267433

A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission Dr. Locke Bryan   Mantle Cell Lymphoma III

S1826

ClinicalTrials.gov: #

NCT03907488

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in
Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Dr. Locke Bryan   Advanced Stage Classical Hodgkin Lymphoma III

ADCT-402-103

ClinicalTrials.gov: #

NCT03684694

A Phase 1b Open-Label Study to Evaluate the Safety and Antitumor Activity of Loncastuximab Tesirine and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Dr. Locke Bryan  

Large B-Cell Lymphoma

Mantel Cell Lymphoma

Ib

5F9003

ClinicalTrials.gov: #

NCT02953509

A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Dr. Locke Bryan   Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Ib/II

Myeloproliferative Neoplasms (MPN)

Protocol ID

Official Name

Principal Investigator

Lead CRC

Disease Site

Phase

Actuate 1901

ClinicalTrials.gov #

NCT04218071

Phase 2 study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) inhibitor, as a single agent or combined with Ruxolitinib, in patients with myelofibrosis Dr. Jorge Cortes   Myelofibrosis II

M16-191

ClinicalTrials.gov #

NCT04472598

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1) Dr. Jorge Cortes   Myelofibrosis III

M20-178

ClinicalTrials.gov #

NCT04468984

A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis (TRANSFORM-2) Dr. Jorge Cortes   Myelofibrosis III

Stem Cell Transplant

Protocol ID

Official Name

Principal Investigator

Lead CRC

Disease Site

Phase

INCB-39110-309

ClinicalTrials.gov #

NCT03584516

A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-
Versus-Host Disease
Dr. Vamsi Kota   Chronic Graft-Versus-Host Disease III